A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Active, not recruiting

• Conditions: Thyroid Cancer
• Interventions: Diagnostic Test: Cerenkov luminescence imaging.

• Registration Number: NCT03484884
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-20
• Study First Submitted: 2018-03-20
• Study First Submitted QC: 2018-03-26
• Study First Posted: 2018-04-02
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-02
• Last Update Posted: 2025-01-03
• Primary Completion: 2026-03
• Study Completion: 2026-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

• Participant is 18 years of age or old

• Participant must meet one of the following:

  • Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I
  • Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan
  • Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra
  • Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi PET scan in the Nuclear Medicine Clinic
  • Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic

Exclusion Criteria

• Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes
• Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Thyroid cancer/nodal metastasis	Cerenkov luminescence imaging.	Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.

Primary Outcome Measures

Name	Time	Method
Feasibility of clinical Cerenkov luminescence imaging by achieving satisfactory imaging at least a rate of 80%	Through study completion, an average of 24 hours	The primary objective is to explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical FDG PET or 131I therapy.

Trial Locations

Locations (1)

Memorial Sloan - Kettering Cancer Center; 🇺🇸 New York, New York, United States